Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: AbbVie

Revenues up 14% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie
4Q Revenues: $7.7 billion (+14%)
4Q Earnings: $52.0 million (earnings were $1.4 billion 4Q16)
FY Revenues: $28.2 billion (+10%)
FY Earnings: $5.3 billion (-11%)
Comments: Global HUMIRA sales increased 14% in the quarter to $4.9 billion. Global IMBRUVICA sales were $708 million, up 39%. HCV franchise sales were up 63% to $510 million. Lupron sales were $224 million, up 2%. Creon sales were $235 million, up 11%. AndroGel sales were down 20% to $140 million, impacted by liability litigation due to safety concerns. Kaletra sales were down 14% to $113 million. Results for 2017 included the one-time impact of approximately $4.5 billion for taxation on previously unrepatriated earnings.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters